Your session is about to expire
← Back to Search
General Anesthetic
Anesthesia Choice for Gynecologic Cancer Surgery
Phase 4
Recruiting
Led By Nelson Algarra, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects must be cleared for surgery by the pre-anesthesia clinic
Be older than 18 years old
Must not have
Subjects with a previous treatment of diagnosis of increased intraocular pressure
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day of surgery
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing whether total IV anesthesia decreases intraocular pressure during robotic cancer surgery in the Trendelenburg position.
Who is the study for?
This trial is for women over 18 who are set to have robotic surgery for suspected or confirmed gynecological cancer. They must be cleared by the pre-anesthesia clinic and agree to all study procedures. It's not open to those with certain eye conditions, recent eye surgery, or known high intraocular pressure.
What is being tested?
The study measures how much a woman's eye pressure changes during robotic cancer surgery when using two types of anesthesia: total IV anesthesia (TIVA) versus conventional balanced anesthesia. The goal is to see which method better prevents an increase in eye pressure.
What are the potential side effects?
While specific side effects aren't listed, general risks may include typical anesthesia reactions such as nausea, drowsiness post-surgery, sore throat from breathing tubes, and less commonly, more serious complications like allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been cleared for surgery by the anesthesia team.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been treated or diagnosed for high eye pressure before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day of surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day of surgery
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Quantify the degree of change in intra ocular pressure in female patients undergoing robotic procedures
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: TIVA anesthesiaExperimental Treatment1 Intervention
Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, intravenous infusion of propofol, lidocaine, ketamine or narcotic as deemed appropriate by anesthesiologist. There will be no inhalation anesthetic used. Ventilation with oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During surgery, mechanical ventilation using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
Group II: Balanced anesthesiaActive Control1 Intervention
Induction with 1% propofol (2-3 mg/kg), fentanyl (1-3 mg/kg), and Rocuronium 1-1.5 mg/kg. Before the injection of propofol, 5 mL 1% lidocaine (50 mg) to limit any discomfort caused by the propofol injection. After endotracheal intubation, the depth of anesthesia will be maintained at a minimum alveolar concentration of 1 to 1.25 using isoflurane in oxygen and air mixture (50%/50%) and titrated to keep the mean arterial pressure within 20% of its preinduction value. Muscle relaxation maintain using Aliquots of rocuronium to 0 to 1 train-of-4 twitch response of adductor pollicis. During the surgery, subjects will be mechanically ventilated using pressure-controlled mode (peak inspiratory pressure 30 cm H2O). We aim for Tidal volume of 5-7 ml/Kg of ideal body weight with a positive end-expiratory pressure of 5 cm H2O, and a respiratory rate to maintain end-tidal carbon dioxide between 30 to 40 mm Hg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TIVA
2019
Completed Phase 4
~460
Find a Location
Who is running the clinical trial?
University of FloridaLead Sponsor
1,397 Previous Clinical Trials
766,960 Total Patients Enrolled
Nelson Algarra, MDPrincipal InvestigatorUniversity of Florida
1 Previous Clinical Trials
90 Total Patients Enrolled
Sonia Mehta, MDPrincipal InvestigatorUniversity of Florida
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am scheduled for robotic surgery for suspected or confirmed gynecological cancer.I have been cleared for surgery by the anesthesia team.I am over 18, have a gynecological cancer, and am cleared for surgery.I have high eye pressure or recent eye surgery, making eye pressure tests not possible.I have been treated or diagnosed for high eye pressure before.I am a woman aged 18 or older.I have not had eye surgery in the last 30 days.
Research Study Groups:
This trial has the following groups:- Group 1: Balanced anesthesia
- Group 2: TIVA anesthesia
Awards:
This trial has 3 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger